Related Experiment Video
Updated: May 22, 2026

Differentiated Mouse Adipocytes in Primary Culture: A Model of Insulin Resistance
Published on: February 17, 2023
Retinoids ameliorate insulin resistance in a leptin-dependent manner in mice
Hiroyuki Tsuchiya1, Yoshito Ikeda, Yu Ebata
1Department of Biophysical Chemistry, Kyoto Pharmaceutical University, Kyoto, Japan. tsuchiya@mb.kyoto-phu.ac.jp
Unlabelled:
Transgenic mice expressing dominant-negative retinoic acid receptor (RAR) α specifically in the liver exhibit steatohepatitis, which leads to the development of liver tumors. Although the cause of steatohepatitis in these mice is unknown, diminished hepatic expression of insulin-like growth factor-1 suggests that insulin resistance may be involved. In the present study, we examined the effects of retinoids on insulin resistance in mice to gain further insight into the mechanisms responsible for this condition. Dietary administration of all-trans-retinoic acid (ATRA) significantly improved insulin sensitivity in C57BL/6J mice, which served as a model for high-fat, high-fructose diet-induced nonalcoholic fatty liver disease (NAFLD). The same effect was observed in genetically insulin-resistant KK-A(y) mice, occurring in concert with activation of leptin-signaling pathway proteins, including signal transducer and activator of transcription 3 (STAT3) and Janus kinase 2. However, such an effect was not observed in leptin-deficient ob/ob mice. ATRA treatment significantly up-regulated leptin receptor (LEPR) expression in the livers of NAFLD mice. In agreement with these observations, in vitro experiments showed that in the presence of leptin, ATRA directly induced LEPR gene expression through RARα, resulting in enhancement of STAT3 and insulin-induced insulin receptor substrate 1 phosphorylation. A selective RARα/β agonist, Am80, also enhanced hepatic LEPR expression and STAT3 phosphorylation and ameliorated insulin resistance in KK-A(y) mice.
Conclusion:
We discovered an unrecognized mechanism of retinoid action for the activation of hepatic leptin signaling, which resulted in enhanced insulin sensitivity in two mouse models of insulin resistance. Our data suggest that retinoids might have potential for treating NAFLD associated with insulin resistance.
Insights
Retinoids, like all-trans-retinoic acid (ATRA), enhance insulin sensitivity by activating hepatic leptin signaling. This mechanism improves insulin resistance in models of nonalcoholic fatty liver disease (NAFLD) and suggests retinoids as potential treatments.
Area of Science:
- Hepatology
- Endocrinology
- Molecular Biology
Background:
- Dominant-negative retinoic acid receptor alpha (RARα) in liver causes steatohepatitis and liver tumors in mice.
- Diminished insulin-like growth factor-1 suggests insulin resistance may underlie this condition.
Purpose of the Study:
- To investigate the effects of retinoids on insulin resistance.
- To elucidate the mechanisms by which retinoids influence insulin sensitivity.
Main Methods:
- Dietary administration of all-trans-retinoic acid (ATRA) to C57BL/6J (NAFLD model) and KK-A(y) mice.
- Assessment of insulin sensitivity, leptin signaling pathway proteins (STAT3, JAK2), and leptin receptor (LEPR) expression.
- In vitro experiments using ATRA and a selective RARα/β agonist (Am80).
Main Results:
- ATRA improved insulin sensitivity in NAFLD and KK-A(y) mice, correlating with STAT3 and JAK2 activation.
- The effect was absent in leptin-deficient ob/ob mice, highlighting the role of leptin signaling.
- ATRA upregulated hepatic LEPR expression and, in vitro, directly induced LEPR gene expression via RARα, enhancing STAT3 and insulin signaling.
Conclusions:
- Retinoids activate hepatic leptin signaling, enhancing insulin sensitivity through an unrecognized mechanism.
- This action was observed in two mouse models of insulin resistance.
- Retinoids show potential for treating nonalcoholic fatty liver disease (NAFLD) associated with insulin resistance.
More Related Videos
Related Concept Videos
Oral Hypoglycemic Agents: Biguanides and Glitazones
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Insulin: The Receptor and Signaling Pathways
Type II Diabetes II: Pathophysiology
Dipeptidyl Peptidase 4 Inhibitors

